Sector News

Illumina appoints Dr. Frances Arnold to its board of directors

January 29, 2016
Life sciences

(BUSINESS WIRE) – Illumina, Inc. today announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.

Dr. Arnold joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor and Director. Her laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals and medicine.

“We are very pleased to welcome Dr. Arnold to our board and look forward to leveraging her experience and expertise in life sciences and medicine,” said Jay Flatley, Illumina Chief Executive Officer. “We value the perspective and passion that she will bring to the role as we plan for growth in our clinical and research markets.”

Dr. Arnold is the recipient of numerous honors, including induction into the National Inventors Hall of Fame (2014), Fellow of the National Academy of Inventors (2014), the ENI Prize in Renewable and Nonconventional Energy (2013), the US National Medal of Technology and Innovation (2011), and the Charles Stark Draper Prize of the US National Academy of Engineering (2011). She has been elected to membership in all three US National Academies, of Science, Medicine, and Engineering and the American Academy of Arts and Sciences.

Source: Illumina

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.